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Abstract: BACKGROUND: Ultrasound (US)-guided breast biopsy is a routine diagnostic method used to
correlate imaging finding to a histological diagnosis which is still the gold standard in preoperative diag-
nostics. The accuracy of US-guided breast biopsies relies on a precise radiologic-histopathologic correla-
tion, which is discussed amongst an interdisciplinary team of gynecologists, radiologists and pathologists.
However, false-negative or non-diagnostic biopsy results occur. Hence, a thorough and honest discussion
to clarify the reason for discrepancies and to decide the next diagnostic step between specialists of the
different disciplines is warranted. In this retrospective study, we analyzed discrepant findings between
imaging and pathology results on preoperative breast biopsies. METHODS: Core and vacuum-assisted
breast biopsies from 232 patients were included in this study. Inclusion criteria were (1) non-diagnostic
(B1) category on histology independent from imaging category and (2) histological benign (B2) cate-
gory with a BIRADS 5 (Breast Imaging Reporting and Data System) rating on imaging. Histological
diagnoses were retrieved from all cases. Follow-up data were available in most cases. RESULTS: 138
biopsies were classified as B1, 94 biopsies as B2 category. 51 of 138 B1 cases (37%) underwent re-biopsy.
Re-biopsy found malignancy (B5) in 19 of 51 cases, and B3/4 (premalignant) lesions in 3 of 51 cases. All
B2 cases underwent second-look imaging-diagnosis, in 57 of 94 cases (66%) consecutive direct surgery or
re-biopsy. Of these, malignancy was diagnosed histologically in 26 of 57 cases (45.6%). CONCLUSION:
Determining imaging-pathology concordance after US-guided breast biopsy is essential. Discrepant cases
and further diagnostic steps need to be discussed with an interdisciplinary approach.
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Abstract
Background Ultrasound (US)-guided breast biopsy is a routine diagnostic method used to correlate imaging finding to a 
histological diagnosis which is still the gold standard in preoperative diagnostics. The accuracy of US-guided breast biopsies 
relies on a precise radiologic-histopathologic correlation, which is discussed amongst an interdisciplinary team of gynecolo-
gists, radiologists and pathologists. However, false-negative or non-diagnostic biopsy results occur. Hence, a thorough and 
honest discussion to clarify the reason for discrepancies and to decide the next diagnostic step between specialists of the 
different disciplines is warranted. In this retrospective study, we analyzed discrepant findings between imaging and pathol-
ogy results on preoperative breast biopsies.
Methods Core and vacuum-assisted breast biopsies from 232 patients were included in this study. Inclusion criteria were 
(1) non-diagnostic (B1) category on histology independent from imaging category and (2) histological benign (B2) category 
with a BIRADS 5 (Breast Imaging Reporting and Data System) rating on imaging. Histological diagnoses were retrieved 
from all cases. Follow-up data were available in most cases.
Results 138 biopsies were classified as B1, 94 biopsies as B2 category. 51 of 138 B1 cases (37%) underwent re-biopsy. Re-
biopsy found malignancy (B5) in 19 of 51 cases, and B3/4 (premalignant) lesions in 3 of 51 cases. All B2 cases underwent 
second-look imaging-diagnosis, in 57 of 94 cases (66%) consecutive direct surgery or re-biopsy. Of these, malignancy was 
diagnosed histologically in 26 of 57 cases (45.6%).
Conclusion Determining imaging-pathology concordance after US-guided breast biopsy is essential. Discrepant cases and 
further diagnostic steps need to be discussed with an interdisciplinary approach.
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Introduction
US-guided biopsy on palpable and non-palpable breast 
lesions is a routine diagnostic tool in the preoperative 
setting. Core needle biopsy (CNB) is less invasive than 
vacuum-assisted biopsy (VAB) and therefore fewer sur-
gical complications are expected (Mihalik et al. 2010). 
In the case of benign findings in the biopsy, unnecessary 
surgery can be avoided. In addition, the cost of a biopsy 
is lower than that of an open surgical excision (Kim et al. 
2008). In case of malignant findings, weekly preoperative 
senology boards provide recommendations on the basis 
of which individual options can then be discussed with a 
patient. These also depend on age, tumor stage, receptor 
status and of course, the patient’s wishes.
The key of a successful core biopsy workflow is an 
excellent communication and a high level of agreement 
among attending radiologists, pathologists and gynecolo-
gists (Hahn et al. 2012; Parikh and Tickmann 2005). The 
breast sonographer is the most experienced in evaluation 
of abnormal findings, thus playing an essential role in 
the diagnostic process. Preferably, the same person who 
detected the lesion concurrently performs the biopsy 
to ensure accurate analysis of the lesion. This continu-
ity helps to ensure the lesion recommended for biopsy is 
the one that actually undergoes biopsy as well as a direct 
assessment of its technical adequacy. The pathologist is 
crucial in assessing and communicating the quantitative 
and qualitative aspects of the biopsy. Literature shows the 
frequency of missed cancers in trials ranges from 0.3 to 
8.2%, with approximately 70% being identified immedi-
ately after core biopsy. Thirty percent are delayed false-
negative stereotactic breast biopsies where a further biopsy 
is needed in 9–18% of patients (Mihalik et al. 2010).
Since the 2003 edition of the BIRADS was published, 
the BIRADS lexicon and classification have proven to be 
useful in predicting the likelihood of malignancy in radio-
logically assessed breast lesions (Kim et al. 2008; Lee 
et al. 2008; Park et al. 2018). Each BIRADS assessment 
category indicates an anticipated likelihood of malignancy, 
which is based on a thorough evaluation of the imaging 
features Kim et al. 2008, Lee et al. 2008.
Category 3 (probably benign) is reserved for specific 
imaging findings known to have a likelihood of malig-
nancy of > 0% but ≤ 2%. Such lesions include solid masses 
with a circumscribed margin, oval shape and parallel 
orientation; complicated cysts and clustered microcysts 
(Mendelson et al. 2013). Although the recommended man-
agement is imaging follow-up, CNB can be performed 
under certain circumstances. For category 3 lesions, a 
benign (B2) biopsy result can be regarded as concord-
ant with the images. Malignant biopsy results (B5) are 
considered to be discordant, but the sonographic features 
should be reviewed for subtle suspicious imaging features 
that might have been overlooked in the first place (Youk 
et al. 2011).
Category 4 (suspicious of malignancy) covers a wide 
range of likelihood of malignancy, ranging from 2 to 95%. 
Thus, almost all recommendations for image-guided breast 
interventions come from assessments made using this cat-
egory. Starting in the fourth edition of BIRADS and main-
tained in its recent fifth edition, category 4 is subdivided 
into 4A, 4B, and 4C (Mendelson et al. 2013). The range of 
the likelihood of malignancy is > 2% and ≤ 10% for category 
4A, > 10% and ≤ 50% for category 4B, and > 50% and < 95% 
for category 4C. Although the subcategorization of sono-
graphic BIRADS category 4 has been reported to be use-
ful in predicting the likelihood of malignancy, established 
objective criteria do not exist for the subcategories and inter-
observer agreement has been shown to be poor (Mihalik 
et al. 2010; Youk et al. 2010).
Category 5 (highly suggestive of malignancy) carries 
a very high probability (≥ 95%) of malignancy, and any 
benign percutaneous tissue diagnosis should be considered 
discordant.
The histopathological B classification is defined in an 
analogous way, such as B1 (not diagnostic), B2 (benign), 
B3 (lesions with uncertain potential), B4 (suspicious of 
malignancy) and B5 (malignant) (AGO (2020); S3 Leitlin-
ien 2020; Breast Cancer Screening Program NSH 2020).
In this study, we systematically analyzed discrepant diag-
noses between radiological and histological findings, focus-
ing on non-diagnostic biopsies (in all BIRADS categories) 
and on malignant imaging diagnosis (BIRADS 5) with his-
tologically benign lesions (B2 lesions).
Materials and methods
Patient cohort
In total, 232 patients were included in this study. The cohort 
was retrieved from diagnostic files from the Institute of 
Pathology and Molecular Pathology, University Hospital 
Zurich, where between 2010 and 2019 more than 10,000 
diagnostic breast biopsies were performed.
The study was covered by a valid ethical approval (Zurich 
Cantonal Ethical Committee, KEK–2012–554 including 
regulation on informed consents).
Following groups were analyzed:
First group: Patients who were biopsied because of radio-
logical lesions classified from BIRADS 2 to BIRADS 5, 
where a B1 lesion was reported in the histology.
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Second group: Patients who were biopsied because of 
radiological lesions classified as BIRADS 5 where a B2 
lesion was diagnosed in the histology.
Results
B1 histological findings and any BIRADS category
This group encompassed 138 cases. Patients underwent 
breast core biopsies because of radiological findings from 
BIRADS 2 to BIRADS 5 lesion and histological results that 
showed non-diagnostic B1 lesions.
Ten biopsies were carried out for BIRADS 2 lesion, 45 
biopsies for BIRADS 3, 31 biopsies for BIRADS 4 and 7 
biopsies for BIRADS 5 imaging categories. In 45 patients, 
the radiological findings were suspicious for malignancy 
without documented BIRADS classification (Fig. 1a).
The BIRADS category prior to the US-guided CNB 
was established by ultrasound diagnostics (in 129 cases), 
ultrasound in addition to mammography in 7 cases, and 
ultrasound in addition to MRI in 2 cases. The initial biopsy 
was always US-guided CNB with 3–5 cores.
Histological findings showed fat/connective tissue in 60 
cases (43%) followed by skeletal muscles (5 cases), scar 
tissue (3 cases), normal breast tissue (11 cases), ductec-
tasia (2 cases), fibrosis (35 cases), inflammation (1 case) 
and necrosis (1 case). In 23 cases, there was no evidence 
of breast tissue in the biopsy (Fig. 1b).
Fig. 1  The following diagnostic imaging (a) and histological (b) diagnoses were found in the primary biopsy with B1 diagnostic category
Fig. 2  Re-biopsy rate after B1 
histological category (a) and 
distributions of B-category in 
re-biopsies after B1 diagnostic 
category (b)
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51 out of 138 patients (37%) underwent re-biopsy 
(Fig. 2a).
Out of the 51 cases which were re-biopsied, 19 (37%) 
were diagnosed as B5, one (2%) as B4, 4 (8%) as B3 and 
27 (53%) as benign lesions (Table 1, Fig. 2b).
Histological B2 category and radiological BIRADS 5 
lesions
This group consisted of patients with BIRADS 5 in imaging 
and a B2 diagnosis in histology. We identified 94 biopsies 
matching this category. The distribution of discrepancies 
between BIRADS 5 and histologically benign lesions var-
ied from 6 to 16 cases per year (Fig. 3). In more than half 
of these cases (55%), mastopathic changes were identified: 
fibrosis in 39 of 94 patients (36%) and adenosis in 18 of 
94 cases (19%). Other frequent diagnoses included fibroad-
enoma, fat tissue necrosis, chronic inflammation and scar 
formation in the remaining 45% of B2 biopsies (Table 2). 
The BIRADS category prior to the US-guided CNB was 
established on ultrasound in 83 cases, ultrasound in addition 
to mammography in 9 cases, ultrasound in addition to MRI 
in 1 case and ultrasound in addition to PET CT in 1 further 
case. Initial biopsy was always US-guided CNB with 4–5 
cores.
In 57 of the 94 cases, further diagnostics were carried out 
including a radiology-pathology correlation, US and in some 
cases MRI (60.6% of all BIRADS 5 cases). Interestingly, 
from 2010 to 2012, radiologically suspicious but histologi-
cally benign (B2) lesions most frequently were handled by 
open surgery, while from 2012 to 2016, a re-biopsy with 
CNB was performed, and from 2017 to 2019, VAB increas-
ingly was used for discordant findings (Fig. 4a). Of the 57 
cases, which were followed up by further diagnostics as 
described above, malignancy was confirmed histologically 
in 26 cases (45.6%) (Fig. 4b).
Discussion
In this study, we analyzed cases in which a discordance 
between radiological (probably malignant or malignant) 
and histological (benign) findings was observed. A case 
was included when imaging features of a lesion that were 
suspicious for malignancy (i.e., BIRADS category 4 or 
5), corresponded to benign histology (B2 category) in the 
CNB. The reported percentages of imaging-pathology dis-
cordant lesions among breast CNB range from 2.0 to 19.2% 
(Soyder et al. 2015; Sohn et al. 2014; Youk et al. 2010; Son 
et al. 2011). Histologically benign lesions with speculated 
findings, such as granular cell tumor, sclerosing adenosis, 
post-surgical scar, fatty necrosis, mastitis, diabetic mastop-
athy and sarcoidosis, can mimic malignancy on US (Cho 
and Park 2013; Kim et al. 2007). In our cohort, approxi-
mately half of BIRADS-5 cases turned out to be malignant 
Table 1  Histological diagnoses 
in re-biopsies after B1 category
Re-biopsy category (after B1 
diagnosis)
n Histology
B2 27 (53%) Benign histology
B3 4 (8%) Classical lobular neoplasia (LN) (n = 2)
Flat epithelial atypia (FEA) (n = 2)
B4 1 (2%) Atypical ductal hyperplasia (ADH)
B5 19 (37%) DCIS (n = 3)
Solid papillary carcinoma (n = 1) 
NST carcinoma (n = 11)
Lobular carcinoma (n = 4)
Fig. 3  Yearly distribution of BIRADS 5—B2 biopsy categories over 
a 10-year period
Table 2  Histological diagnoses 
in the discrepant categories 
BIRADS 5 and B2 benign 








usual ductal hyperplasia 
(UDH)
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in re-biopsy or in open surgery, and the other half were con-
firmed benign.
The histopathological B classification is defined in sev-
eral classification systems, such as the NHS Breast Cancer 
Screening program, the AGO guidelines, the S3 guidelines 
and also by the Minimal Invasive Breast Biopsy (MIBB) 
classification (AGO (2020); S3 Leitlinien 2020; Breast Can-
cer Screening Program NSH 2020). Category B1 is defined 
as normal tissue, lack of orientating breast parenchyma or 
insufficient tissue. Category B2 applies to benign lesions 
(such as fibroadenoma, usual ductal hyperplasia, fibrosis and 
cysts, among others). Category B3 encompasses biologi-
cally uncertain lesions (such as flat epithelial atypia, atypical 
ductal hyperplasia, classical lobular neoplasia, radial scar 
and benign/borderline phyllodes tumors). Category B4 is 
usually applied when a DCIS (or at least an ADH) is sus-
pected, and category B5 describes malignancy (AGO 2020; 
S3 Leitlinien 2020).
The question of whether the BIRADS 5 category on ultra-
sound and/or mammography scans is correctly applied or is 
set too high for discrepant lesions, can only be answered by 
directly correlating the histological and the imaging findings 
in each given case (Parikh and Tickmann 2005; Son et al. 
2011; Park et al. 2018).
Category B1 with normal breast tissue may indicate that 
the target lesion was not reached by the US-guided CNB. 
The documentation of the performance of the biopsy with 
regard to the US image (an ultrasound picture of the biopsy 
needle within the target lesion) is therefore of utmost impor-
tance. Sufficient experience in US-guided CNB has been 
shown to decrease the rate of misguided target lesions (Li 
et al. 2010; Mihalik et al. 2010). Especially in discordant 
cases, the size of the CNB should be considered as thin-
ner needles may potentially contribute to missed lesions (Li 
et al. 2010; Mihalik et al. 2010).
Sonographic findings in special situations, such as scar-
ring—as well as post-operative and post-irradiation con-
nective tissue changes—may pose an even more difficult 
imaging interpretation, especially in view of the differential 
diagnosis of a recurrent lesion (Park et al. 2018). In discrep-
ant cases, it is also essential for pathologists to re-view B1 
and B2 diagnostic categories on the histological slides.
The interdisciplinary direct communication and feed-
back between the radiologist/gynecologist and patholo-
gist is of utmost importance to enhance the learning effect 
and to clarify the reason for discrepant findings (Park et al. 
2018; Mihalik et al. 2010; Soyder et al. 2015; Sohn et al. 
2014; Youk et al. 2010).
In our study, more than half of initially discordant lesions 
that were biopsied with US-guided CNB were confirmed be 
malignant in subsequent open excision, VAB or re-biopsy 
(Mihalik et al. 2010; Soyder et al. 2015; Sohn et al. 2014; 
Youk et al. 2010). Discordant benign histological findings 
need to be immediately discussed between the performing 
radiologist/senologists and the interpreting pathologist, 
ideally even within an interdisciplinary preoperative seno-
logical board to clarify the discrepancy. Based on the deci-
sion of the multidisciplinary board, the radiologist should 
communicate with the referring physician as well as with 
the patient and discuss the need—or the lack thereof—for 
a repeated biopsy (Mihalik et al. 2010; Soyder et al. 2015; 
Sohn et al. 2014; Youk et al. 2010; Park et al. 2018; Parikh 
and Tickmann 2005).
In addition to CNB, a US-guided VAB has been shown to 
be a valuable alternative to open surgery for breast lesions 
with imaging-pathology discordance with an upgrade rate 
from 4.6 to 22.7% (Kim et al. 2012; Li et al. 2010; Wang 
et al. 2011). Therefore, both CNB and US-guided VAB 
can be an option for repeated biopsies of discordant benign 
lesions. The best biopsy method should be determined indi-
vidually after consultation among the radiologists, patholo-
gists, referring physicians and the patient.
Fig. 4  Repeat diagnostic proce-
dure after benign (B2) histology 
at BIRADS 5 imaging category 
(a) and malignancy rate in 
re-biopsies/primary surgery 
after benign (B2) histology at 
BIRADS 5 imaging category 
(b)
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Conclusion
US-guided breast CNB is an accurate method for diagnos-
ing breast cancer, with a false-negative rate ranging from 
0.1 to 2.5%. Determining imaging-pathology concordance 
after US-guided breast CNB is essential and needs to be 
addressed within an interdisciplinary preoperative confer-
ence. Discrepant findings should undergo a second-look 
review of imaging and histological findings, and the next 
consecutive diagnostic step should be decided within an 
interdisciplinary team. Appropriate management, includ-
ing active communication between the pathologist, referring 
physician and patient, should be carried out accordingly.
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